---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096127"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:12.115110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024

## Summary
- Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.
- R&D expenses fell to $0.6M from $14.4M due to suspension of mavodelpar development and workforce cuts.
- Merger with OnKure (all-stock) plus $65M PIPE expected to close H2 2024; combined cash ~$120M.
- General and administrative expenses $5.8M vs $6.6M, with $2.4M increase in legal/advisory fees for merger.

## SEC filing metadata
- accession: 0000950170-24-096127
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017024096127/0000950170-24-096127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017024096127/rphm-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096127
- JSON: https://secwatch.observer/filing/0000950170-24-096127.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.